A Phase 3 interventional study of Amoxicillin 500 mg / Metronidazole 250 mg and Clindamycin 300 mg in Periodontitis, Periodontal Pocket and Diabetes Mellitus, sponsored by Centro Universitario de Tonalá. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-09-16.
Sponsored by Centro Universitario de Tonalá · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Periodontitis is an inflammation of the supporting structures of the teeth, usually caused by specific or groups of microorganisms that results in the progressive destruction of the periodontal ligament and alveolar bone. the objective of periodontitis treatment is to reduce the number of periodontal pathogens. However, there is not an agreement in the use of systemic antibiotics in patients with diabetes. The purpose of the present study was to determine the efficacy of amoxicillin/metronidazole compared to clindamycin during non-surgical treatment of periodontitis in patients with type 2 diabetes mellitus.
Patients and methods In this double-blind, randomized clinical trial, a total of 42 patients with chronic periodontitis and type 2 diabetes were included in a 24-months follow-up. Patients were randomly assigned to treatment with either amoxicillin/metronidazole or clindamycin every for 7 days. Clinical determinations (depth of probing, bleeding at the probe and plaque index) were performed to determine the extent and severity of periodontitis before and after the pharmacological treatment. The intra-group differences were calculated with Wilcoxon rank test. The inter-group differences were calculated with Mann-Whitney test. Sex, bacterial plaque, and bleed to the sounding were summarized using proportions and analyzed with the chi-square method. In all analyses, a P-value of \<0.05 (two tailed) was considered statistically significant
A parallel, randomized, double-blind, active controlled, single center clinical trial was designed to compare the efficacy of two antibiotic therapies with 24-month follow-up. The study protocol was approved by the ethical committee of the Universitary Center of Health Sciences of University of Guadalajara and conducted according to Good Clinical Practice and the principles of the Declaration of Helsinki. All patients provided written informed consent before the initiation of study procedures.
A total of 5 non-study subjects with chronic periodontitis were recruited and used for the calibration exercise. Two designated examiners measured full-mouth probing pockets depths (PPD) for all 5 subjects. On the same day (with a minimum of 15 min separation), the examiner repeated the examination. Upon completion of all measurements, the intra-examiner repeatability for PPD measurement was assessed. The examiner was judged to be reproducible after fulfilling the pre-determined success criteria (the percentage of agreement within 2 mm between repeated measurements had to be at least 70 %). The examiner showed 78.3 % reproducibility.
The sample size was calculated with a 95% confidence level and statistical power of 80 %. A standard deviation of 1.0 mm with an expected difference of 1.0 mm probing pocket depth reduction between treatments. This resulted in a total of 14 patients per arm, however this sample was increased 20% (21 patients per group) to compensate for possible dropouts.
Patient population Criteria for selection Patients of both sexes (aged >18 to 70 years) with a diagnosis of chronic periodontitis according to the 1999 International World Workshop for a Classification of Periodontal Diseases and Conditions and a history of type 2 diabetes with a HbA1C \< 8 % and a fasting plasma glucose (FPG) \< 180 mg/dL. Patients with aggressive periodontitis, pregnant or lactating females, required antibiotic pre-medication for the performance of periodontal examination and treatment or received antibiotic treatment in the previous 3 months were excluded. A history of anti-inflammatory therapy within preceding six months or that had received a course of periodontal treatment within the last 6 months, allergies to penicillin, metronidazole or clindamycin, and were not able to provide consent to participate in the study were also criteria for exclusion.
Intervention Subjects were randomly allocated 1:1 to receive 500 mg amoxicillin + 250 mg metronidazole or 300 mg clindamycin + placebo using a computer that generated a list of random numbers. Subjects were instructed to take the treatment three times a day for 7 days in both groups.
Assessments During these sessions, a case presentation was given to each subject related to the specific features of his/her disease, as well as a supra- and sub-gingival mechanical debridement was performed. A complete periodontal examination was performed, including a full medical and dental history, an intra-oral examination and a full-mouth periodontal probing. A radiographic examination was undertaken using either periapical x-rays or a ortopantomography.
Clinical parameters Clinical parameters were assessed using a North Caroline Periodontal Probe by the calibrated examiner at six sites. Full-mouth plaque scores were recorded by assigning a binary score to each surface (1 for plaque present, 0 for absent) and by calculating the percentage of total tooth surfaces that revealed the presence of plaque detected by the use of tablet. Similarly, a full-mouth percentage bleeding score was calculated after assessing dichotomously the presence of bleeding on probing from the bottom of the pocket when probing with a manual probe with a force of 0.3n. Full-mouth PPD and recession of the gingival margin were recorded at the same time with measurements rounded to the nearest millimeter.
Non-surgical periodontal therapy Periodontal therapy was initiated within 1 month of the baseline screening examination. A standard cycle of periodontal therapy consisting of oral hygiene instructions, supra- and sub-gingival mechanical instrumentation of the root surface (scaling and root planning) was performed by two experienced therapists.
Local anesthesia was used as necessary. Patients relied on standard oral hygiene methods as instructed at the commencement of the study.
Post-treatment controls The objectives of the post-treatment appointments were to control and reinforce the oral hygiene habits of each subject, to monitor the early healing events and to report any adverse events or additional medications taken. In addition, the 1-week post-treatment visit served as a compliance control, as subjects were asked to return any medication not taken and/or the empty bottles. The number of pills not taken by the study subjects was documented.
Re-assessment examinations Reassessment visits occurred within a month and a half of the completion of the pharmacological treatment. During these appointments, the examiner recorded any changes in the medical history and repeated clinical periodontal parameters recorded at the basal visit.
Statistical analysis Age, FPG, HbA1C, tooth, and sounding depth were presented in means and standard deviation. The intra-group differences were calculated with Wilcoxon rank test. The inter-group differences were calculated with Mann-Whitney test. Sex, bacterial plaque, and bleed to the sounding were summarized using proportions and analyzed with the chi-square method. In all analyses, a P-value of \<0.05 (two tailed) was considered statistically significant. All statistical analyses were conducted using SPSS software (IBM Corporation, Armonk, NY, USA) version 21.
130 studies on the registry are indexed under Periodontal Pocket; 35 are open to participants now.
This study's enrollment of 42 is above the median of 30 across 113 interventional studies indexed under Periodontal Pocket.
Browse Periodontal Pocket studies →Centro Universitario de Tonalá is the lead sponsor of 5 studies on the registry; none are open to participants now.
Compared within Periodontal Pocket, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Periodontitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AMX-MET Amoxicillin 500 mg + Metronidazole 250 mg. Capsules. 1 capsule tid during 7 days.
Drug: Amoxicillin 500 mg / Metronidazole 250 mg
Clindamycin Clindamycin 300 mg + placebo. Capsules. 1 capsule tid during 7 days.
Drug: Clindamycin 300 mg
Drug page: Amoxicillin
Subjects were instructed to take a capsule three times a day for 7 days
Subjects were instructed to take a capsule three times a day for 7 days
Probing Depth
The size of the periodontal pocket
Time frame: 7 days
Sites With Plaques
0: no plaque 1. separate flecks of plaque at the cervical margin of the tooth 2. a thin continuous band of plaque (up to 1 mm) at the cervical margin of the tooth 3. a continuous band of plaque wider than 1 mm but covering less than one-third of the crown of the tooth 4. plaque covering at least one-third but less than two-thirds of the crown of the tooth 5. plaque covering two-thirds or more of the crown of the tooth. A higher scores mean a worse outcome
Time frame: 7 days
Sites With Bleeding on Probing
Refers to bleeding on probing 0: absence of inflammation 1. mild inflammation; a slight change in color, little change in the texture of any portion of but not the entire marginal or papillary gingival unit 2. mild inflammation; criteria as above but involving the entire marginal or papillary gingival unit 3. moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit 4; severe inflammation; marked redness, edema, and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration
Time frame: 7 days
Total Count of All Teeth Lost Across All Participants
The total count of all teeth lost in all participants.
Time frame: 2 years
The study was carried out on patients at the Integral Dentistry Clinics of the University Center of Health Sciences of the University of Guadalajara in Jalisco, Mexico. The participants attended for dental care from August 2015 to December 2016.
| Milestone | AMX-MET | Clindamycin |
|---|---|---|
| Started | 21 | 21 |
| Completed | 21 | 21 |
| Not completed | 0 | 0 |
The size of the periodontal pocket
| mm | AMX-MET | Clindamycin |
|---|---|---|
| Probing Depth | 0.44 ± 0.27 | 0.50 ± 0.17 |
0: no plaque 1. separate flecks of plaque at the cervical margin of the tooth 2. a thin continuous band of plaque (up to 1 mm) at the cervical margin of the tooth 3. a continuous band of plaque wider than 1 mm but covering less than one-third of the crown of the tooth 4. plaque covering at least one-third but less than two-thirds of the crown of the tooth 5. plaque covering two-thirds or more of the crown of the tooth. A higher scores mean a worse outcome
| Sites | AMX-MET | Clindamycin |
|---|---|---|
| Sites With Plaques | 17.6 ± 13.3 | 15.8 ± 10.0 |
Refers to bleeding on probing 0: absence of inflammation 1. mild inflammation; a slight change in color, little change in the texture of any portion of but not the entire marginal or papillary gingival unit 2. mild inflammation; criteria as above but involving the entire marginal or papillary gingival unit 3. moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit 4; severe inflammation; marked redness, edema, and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration
| Sites | AMX-MET | Clindamycin |
|---|---|---|
| Sites With Bleeding on Probing | 16.1 ± 11.2 | 22.1 ± 12.9 |
The total count of all teeth lost in all participants.
| total count of all teeth lost | AMX-MET | Clindamycin |
|---|---|---|
| Total Count of All Teeth Lost Across All Participants | 0 | 0 |
Collected over The adverse events were collected for 10 days. Seven days during the intervention period and 3 days after the final visit.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AMX-MET | 0/21 (0%) | 0/21 (0%) | 0/21 (0%) |
| Clindamycin | 0/21 (0%) | 0/21 (0%) | 0/21 (0%) |
| Age, Continuous(years) | AMX-MET | Clindamycin | Total |
|---|---|---|---|
| Mean | 52.5 ± 8.0 | 52.0 ± 10.6 | 52.2 ± 9.3 |
| Sex: Female, Male(Participants) | AMX-MET | Clindamycin | Total |
|---|---|---|---|
| Female | 10 | 14 | 24 |
| Male | 11 | 7 | 18 |
| Fasting Plasma Glucose(mg/dL) | AMX-MET | Clindamycin | Total |
|---|---|---|---|
| Mean | 134.1 ± 23.3 | 136.3 ± 25.7 | 135.2 ± 24.2 |
| HbA1C(%) | AMX-MET | Clindamycin | Total |
|---|---|---|---|
| Mean | 7.1 ± 0.4 | 7.3 ± 0.4 | 7.2 ± 0.4 |
| Number of Teeth present in the subjects(Teeth) | AMX-MET | Clindamycin | Total |
|---|---|---|---|
| Mean | 25 ± 3 | 24 ± 5 | 24 ± 4 |
| Probing depth(mm) | AMX-MET | Clindamycin | Total |
|---|---|---|---|
| Mean | 2.4 ± 0.6 | 2.6 ± 0.6 | 2.5 ± 0.6 |
| Sites with Plaque(Sites) | AMX-MET | Clindamycin | Total |
|---|---|---|---|
| Mean | 40.4 ± 22.9 | 40.7 ± 21.9 | 40.5 ± 22.1 |
| Bleeding on Probing(Sites) | AMX-MET | Clindamycin | Total |
|---|---|---|---|
| Mean | 42.4 ± 24.2 | 55.6 ± 25.8 | 49.0 ± 25.6 |
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2014 to primary completion in Jul 2016, 28 months.
Results were first posted in Jun 2020, 3 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clindamycin
Centro Universitario de Tonalá